Teva Recalls 580,000 Blood Pressure Caps Over Cancer-Causing Contaminant

Teva Pharmaceuticals and Amerisource Health Services have initiated a nationwide recall of over 580,000 bottles of Prazosin Hydrochloride capsules used for treating high blood pressure and PTSD-related symptoms due to contamination with N-nitroso Prazosin impurity C, a nitrosamine chemical linked to cancer risk. The recall affects 1 mg, 2 mg, and 5 mg capsule strengths and has been classified by the FDA as Class II, indicating a potential for temporary or medically reversible health effects but a remote likelihood of serious harm. Patients are advised not to stop taking their medication abruptly but should check for affected lot numbers and consult healthcare providers for alternatives. This recall follows a similar recent recall of cholesterol medication from another company, highlighting ongoing challenges in pharmaceutical safety. The FDA and drug makers emphasize safety and quality commitments while urging patients and healthcare providers to monitor the situation closely. Alternatives for blood pressure management are available, and affected patients should work with their doctors to manage their conditions safely during this recall.